PLIVA – PHARM
Pharmacological action – antipsychotic, neuroleptic, antiemetic, sedative.
Reduces manifestations of psychosis: delusions and hallucinations. The antipsychotic effect is associated with the blockade of dopamine D2 receptors in the polyneuronal synapses of the chemoreceptor trigger zone of the brain. Inhibition of dopamine receptors in the nigrostriatal and tubuloinfundibular zones causes extrapyramidal disorders and hyperprolactinemia, central adrenergic and serotonergic receptors – reducing fear, anxiety, stress. Peripheral alpha-adrenergic blocking and H1-histamine blocking effects are manifested by a decrease in blood pressure and antiallergic action. It has a strong sedative, anticholinergic and hypotensive action, moderate antiemetic effect.
Plasma protein binding – 90%. Cmax is achieved in 2–4 hours. It undergoes biotransformation in the liver with the formation of inactive metabolites. Excreted mainly by the kidneys.